Skip to main navigation Skip to search Skip to main content

Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: Study protocol of the 4-year APOSTEL 8 follow-up

  • Larissa Van Der Windt*
  • , Job Klumper
  • , Emilie V.J. Van Limburg Stirum
  • , Janneke Van 'T Hooft
  • , Madelon Van Wely
  • , Aleid G. Van Wassenaer-Leemhuis
  • , Eva Pajkrt
  • , Martijn A. Oudijk
  • , M. A. De Boer
  • , E. S.A. Van Den Akker
  • , A. J.M. Huisjes
  • , J. M. Sikkema
  • , J. Schaaf
  • , H. Visser
  • , D. W.M. Papatsonis
  • , J. J. Zwart
  • , J. O.E.H. Van Laar
  • , J. Baalman
  • , K. S.J. Gordijn
  • , D. P. Van Der Ham
    • K. C. Vollebregt, J. Langenveld, M. S. Post, M. Sueters, H. C.J. Scheepers, R. R. Scholten, N. Van Gemund, M. N. Bekker, Deurloo, M. Knol, F. McAuliffe, K. Walker, APOSTEL 8 Study Group
*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: Study protocol of the 4-year APOSTEL 8 follow-up'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

INIS